Celecoxib
2 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
2
Ongoing
0
Recruiting
0
Completed
2
Sites
7
Countries
1
Endpoints
0
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. ClinicalTrials.gov reports no endpoints for this asset’s linked trials. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
No endpoints are reported by ClinicalTrials.gov for these trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 0 of 0 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
No normalized metric codes are available for this asset.
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
2 of 2
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT00007189Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT) | Celecoxib, Naproxen Alzheimer’s disease | Age ≥70 | Ph 3 | Completed | 6 | May 2007 | 9 | |
| NCT00065169Delaying Alzheimer Disease Symptoms With Anti-Inflammatory Drugs | Celecoxib Alzheimer’s disease | MMSE 26-30 | Not applicable | Completed | 1 | Nov 2005 | - |
Showing 1-2 of 2 trials